Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

October 1, 2019

Study Completion Date

November 14, 2019

Conditions
Venous Thromboembolism
Interventions
DRUG

SelK2

I.V., single-dose

BIOLOGICAL

Enoxaparin

SC, QD for up to 10 ± 2 days

Trial Locations (21)

Unknown

UMHAT Kanev AD, Rousse

Acibadem City Clinic Tokuda Hospital EAD, Sofia

UMHAT Tsaritsa Yoanna - ISUL, Sofia

Regional Hospital of Liepaja, Liepāja

Hospital of Traumatology and Orthopaedics, Riga

ORTO Clinic, Riga

Riga's 2nd Hospital, Riga

Vidzemes Hospital, Valmiera

Kaunas Clinical Hospital, Kaunas

Klaipeda University Hospital, Klaipėda

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok

Samodzielny Publiczny Zakład Opieki Zdrowotnej, Bielsk Podlaski

Szpital Ogólny im. dr Witolda Ginela w Grajewie, Grajewo

Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Krakow

SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi, Lodz

Wojewódzki Szpital Specjalistyczny, Lublin

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Wroclaw

Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council, Cherkasy

Center of Traumatology & Orthopedics, Chernivtsi

Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk

Kiev Regional Clinical Hospital, Kiev

All Listed Sponsors
lead

Tetherex Pharmaceuticals Corporation

INDUSTRY

NCT03812328 - Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement | Biotech Hunter | Biotech Hunter